Table 3.

Changes in the level and trend of the expenditure, volume, and availability for three targeted anticancer drugs and the comparison group.

Molecule	Variables	Expenditure (Log)	Volume (DDDs)	Availability (%)
Rituximab	Baseline difference	2.49 ***	2.92	5.73 ***
		(0.10)	(113.17)	(0.27)
	Baseline trend difference	−0.04	−51.39 *	−0.19 **
		(0.02)	(28.91)	(0.09)
	Difference in level change	0.15	949.60 **	1.56 *
		(0.23)	(415.79)	(0.92)
	Difference in trend change	0.06 *	99.51 *	0.24 *
		(0.03)	(57.66)	(0.13)
Tratuzumab	Baseline difference	2.73 ***	4343.00 ***	2.41 ***
		(0.09)	(336.95)	(0.28)
	Baseline trend difference	−0.04 *	101.57	−0.12 *
		(0.02)	(100.58)	(0.06)
	Difference in level change	−0.11	6765.52	5.24 ***
		(0.25)	(4375.29)	(0.85)
	Difference in trend change	0.15 ***	3673.17 ***	0.66 ***
		(0.04)	(1263.62)	(0.12)
Recombinant Human Endostatin	Baseline difference	1.77 ***	1574.03 ***	5.12 ***
		(0.14)	(295.96)	(0.57)
	Baseline trend difference	−0.05	−9.08	−0.08
		(0.03)	(57.21)	(0.09)
	Difference in level change	−0.06	563.87	0.59
		(0.23)	(538.47)	(0.70)
	Difference in trend change	0.05	30.73	0.32 ***
		(0.04)	(80.61)	(0.11)

Note: Standard errors in parentheses, (*** p < 0.01, ** p < 0.05, * p < 0.1).